All In Biotech

Drug Trial Radar · NCT05224102

A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema

A Phase IV, Multicenter, Open-Label, Single-Arm Study to Investigate Faricimab (RO6867461) Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema

Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

218

Planned (sponsor's estimate)

Start

Feb 28, 2022

Primary completion

Jan 26, 2027

Study completion Jan 26, 2027

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Feb 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab. The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander; in addition, a cohort of Asian Indian participants will be enrolled in India.

Conditions

  • Diabetic Macular Edema

Interventions

  • FaricimabDrug

    Participants will receive 6-milligram (mg) faricimab intravitreal (IVT) injections, as described in the study arm descriptions for each study phase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Main Phase: Change in Best Corrected Visual Acuity (BCVA) from Baseline at Week 56, as Measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at a Starting Distance of 4 MetersTime frame: From Baseline to Week 56
  2. Long-Term Extension Phase: Incidence and Severity of Ocular Adverse EventsTime frame: From Day 1 until end of long-term extension (up to 100 weeks)
  3. Long-Term Extension Phase: Incidence and Severity of Non-Ocular Adverse EventsTime frame: From Day 1 until end of long-term extension (up to 100 weeks)

Locations

43 sites in 4 countries. Site status is shown where the registry gives one.

  • Barnet Dulaney Perkins Eye Center

    Phoenix, Arizona

  • Win Retina

    Arcadia, California

  • Retinal Diagnostic Center

    Campbell, California

  • Retina Consultants of Orange County

    Fullerton, California

  • Kaiser Permanente Southern California

    Los Angeles, California

  • Retinal Consultants Medical Group

    Sacramento, California

  • Southwest Retina Consultants

    Durango, Colorado

  • Emerson Clinical Research Institute LLC

    Washington D.C., District of Columbia

  • Blue Ocean Clinical Research

    Clearwater, Florida

  • Retina Macula Specialists of Miami - LeJeune Road Office

    Miami, Florida

  • Florida Retina Institute

    Orlando, Florida

  • Fort Lauderdale Eye Institute

    Plantation, Florida

  • University Retina and Macula Associates, PC

    Oak Forest, Illinois

  • Wilmer Eye Institute Johns Hopkins University

    Baltimore, Maryland

  • Md Medical Research

    Oxon Hill, Maryland

  • Retina Associates of Michigan

    Grand Blanc, Michigan

  • Retina Consultants of Nevada

    Henderson, Nevada

  • Sierra Eye Associates

    Reno, Nevada

  • The Retina Center of New Jersey

    Bloomfield, New Jersey

  • NJ Retina - Teaneck

    Teaneck, New Jersey

  • Piedmont Retina Specialists

    Winston-Salem, North Carolina

  • Retina Associates of Cleveland, INC

    Beachwood, Ohio

  • Scheie Eye Institute

    Philadelphia, Pennsylvania

  • Wills Eye Hospital

    Philadelphia, Pennsylvania

  • Black Hills Eye Institute

    Rapid City, South Dakota

  • Charles Retina Institute

    Memphis, Tennessee

  • Austin Clinical Research LLC

    Austin, Texas

  • Retina & Vitreous of Texas

    Bellaire, Texas

  • Retina Consultants of Texas Westover Hills Retina Center

    San Antonio, Texas

  • Retina Center of Texas

    Southlake, Texas

  • Strategic Clinical Research Group, LLC

    Willow Park, Texas

  • Piedmont Eye Center

    Lynchburg, Virginia

  • Wagner Kapoor Institute

    Norfolk, Virginia

  • Post Graduate Institute of Medical Education and Research (PGIMER)

    Chandigarh, India

  • MM Joshi Eye Institute

    Hubli, Karnataka, India

  • PBMA'S H. V. Desai Eye Hospital

    Pune, Maharashtra, India

  • M & J Western Regional Institute of Ophthalmology

    Ahmedabad, Rajasthan, India

  • Sankara Nethralaya

    Chennai, Tamil Nadu, India

  • Aravind Eye Hospital

    Madurai, Tamil Nadu, India

  • Regional Institute of Ophthalmology

    Kolkata, West Bengal, India

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.